Dirac Labs Raises $1.8M Pre-Seed

KaliVir Immunotherapeutics

KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs.

ALSO.

We’re ALSO, an electric mobility company on a mission to build the world’s best small vehicles for moving people and goods, driven and autonomous. Originally incubated within Rivian, we’re rethinking transportation from first principles to create a new generation of smaller, smarter, and more connected electric vehicles. Our team combines automotive rigor with advanced software, autonomy, sensing, and vertically integrated EV technologies to build products designed around the realities of modern mobility. We believe small vehicles are not a niche category, but a foundational shift in how people, goods, and communities will move through the world in the decades ahead. At ALSO, details matter. We’re builders, technologists, designers, and dreamers who care deeply about craft, innovation, and the everyday experiences our products create. Because movement is more than transportation—it’s connection, culture, freedom, and collective impact. We’re building that future now.